In Q1 FY2026 (ended March 31, 2026), Tectonic Therapeutic reported a net loss of $25.2 million, an improvement of 58.7% year-over-year. Operating loss was $27.3 million, improving 49.2% from the prior year. Diluted EPS was -$1.34, compared to -$2.40 in Q1 FY2025. The company held $236.9 million in cash and $230.4 million in equity, with no long-term debt.
•Net loss improved 58.7% year-over-year to $25.2 million.
•Operating loss improved 49.2% year-over-year to $27.3 million.
•Diluted EPS of -$1.34 improved from -$2.40 in the prior year.
•Cash and cash equivalents stood at $236.9 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Tectonic Therapeutic, Inc., a biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia. Its portfolio also includes GPCR modulator bispecific for treating fibrosis, and GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. Its lead product candidate is TX45, a Fc-relaxin fusion molecule designed to activate the RXFP1 receptor, which is the GPCR target of the hormone relaxin. Additionally, Tectonic is developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia. The company's pipeline also includes a GPCR modulator bispecific for treating fibrosis and other GPCR modulators.
Where is Tectonic Therapeutic (TECX) listed and in which currency?
Tectonic Therapeutic, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TECX. The company's stock is traded in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange. Investors can buy and sell shares of TECX on NasdaqGM during regular trading hours, with all transactions denominated in USD.
What sector and industry does Tectonic Therapeutic (TECX) operate in?
Tectonic Therapeutic, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies that target GPCRs, which are important cell surface receptors involved in many physiological processes. The company's work involves protein engineering and antibody development, placing it at the forefront of biologic drug discovery for conditions such as fibrosis and vascular disorders.
Where is Tectonic Therapeutic (TECX) headquartered and what markets does it serve?
Tectonic Therapeutic, Inc. is headquartered in Watertown, Massachusetts, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on a US exchange. While its research and development activities are centered in the US, the potential therapies it develops could address global healthcare needs, particularly in areas like fibrosis and hereditary hemorrhagic telangiectasia. However, based on available data, the company's current focus is on the US market.
What are the main product candidates in Tectonic Therapeutic's (TECX) pipeline?
Tectonic Therapeutic's pipeline includes several key product candidates. The lead candidate is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, targeting the GPCR of the hormone relaxin. Another candidate is TX2100, being developed for hereditary hemorrhagic telangiectasia. Additionally, the company is working on a GPCR modulator bispecific for treating fibrosis, as well as other GPCR modulators. These candidates leverage the company's GEODe platform to create biologic medicines that precisely modulate GPCR activity.